See more : Forza Petroleum Limited (FORZ.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Aerie Pharmaceuticals, Inc. (AERI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aerie Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Twentyfirst Century Management Services Limited (21STCENMGM.NS) Income Statement Analysis – Financial Results
- MicroAlgo Inc. (VENA) Income Statement Analysis – Financial Results
- Tritax EuroBox plc (EBOX.L) Income Statement Analysis – Financial Results
- Beijing Beimo High-tech Frictional Material Co.,Ltd (002985.SZ) Income Statement Analysis – Financial Results
- Archidply Industries Limited (ARCHIDPLY.BO) Income Statement Analysis – Financial Results
Aerie Pharmaceuticals, Inc. (AERI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.aeriepharma.com
About Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 194.13M | 83.14M | 69.89M | 24.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 26.85M | 25.33M | 4.83M | 641.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 167.29M | 57.81M | 65.06M | 23.54M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 86.17% | 69.53% | 93.08% | 97.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 75.84M | 74.01M | 91.38M | 86.12M | 72.08M | 52.39M | 44.45M | 29.87M | 11.88M | 9.27M | 10.70M |
| General & Administrative | 0.00 | 137.18M | 138.40M | 120.61M | 73.62M | 44.48M | 30.64M | 20.10M | 10.29M | 5.02M | 3.52M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 137.81M | 137.18M | 138.40M | 120.61M | 73.62M | 44.48M | 30.64M | 20.10M | 10.29M | 5.02M | 3.52M |
| Other Expenses | 0.00 | 2.30M | 22.77M | 26.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 213.64M | 213.50M | 252.55M | 233.28M | 145.69M | 96.87M | 75.09M | 49.97M | 22.17M | 14.29M | 14.22M |
| Cost & Expenses | 240.49M | 238.83M | 257.38M | 233.92M | 145.69M | 96.87M | 75.09M | 49.97M | 22.17M | 14.29M | 14.22M |
| Interest Income | 139.00K | 1.98M | 2.97M | 3.43M | 1.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 28.90M | 26.48M | 15.26M | 2.53M | 2.37M | 2.54M | 2.49M | 628.00K | 3.80M | 75.00K | 109.00K |
| Depreciation & Amortization | 37.50M | 34.16M | 18.11M | 2.44M | 1.41M | 970.00K | 252.00K | 73.00K | 64.00K | 138.00K | 120.00K |
| EBITDA | -7.81M | -117.22M | -166.30M | -227.59M | -143.09M | -95.36M | -71.48M | -47.43M | -27.29M | -14.77M | -12.74M |
| EBITDA Ratio | -4.02% | -141.00% | -237.96% | -941.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -45.31M | -155.69M | -187.49M | -209.74M | -145.69M | -96.87M | -75.09M | -49.97M | -22.17M | -14.29M | -14.22M |
| Operating Income Ratio | -23.34% | -187.27% | -268.27% | -867.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -28.90M | -22.17M | -12.18M | -22.82M | -1.17M | -1.99M | 862.00K | 1.84M | -8.98M | -685.00K | 1.25M |
| Income Before Tax | -74.22M | -177.86M | -199.67M | -232.57M | -146.86M | -98.87M | -74.22M | -48.13M | -31.15M | -14.98M | -12.97M |
| Income Before Tax Ratio | -38.23% | -213.93% | -285.70% | -961.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 593.00K | 5.25M | -90.00K | 3.00K | -1.76M | 193.00K | 139.00K | 2.47M | -5.18M | -610.00K | 1.36M |
| Net Income | -74.81M | -183.10M | -199.58M | -232.57M | -145.11M | -99.06M | -74.36M | -48.13M | -31.15M | -14.98M | -12.97M |
| Net Income Ratio | -38.54% | -220.24% | -285.57% | -961.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.61 | -3.99 | -4.39 | -5.58 | -4.11 | -3.40 | -2.88 | -2.00 | -6.29 | -0.95 | -0.82 |
| EPS Diluted | -1.61 | -3.99 | -4.39 | -5.58 | -4.11 | -3.40 | -2.88 | -2.00 | -6.29 | -0.95 | -0.82 |
| Weighted Avg Shares Out | 46.34M | 45.90M | 45.43M | 41.66M | 35.32M | 29.14M | 25.78M | 24.09M | 4.96M | 15.83M | 15.85M |
| Weighted Avg Shares Out (Dil) | 46.34M | 45.90M | 45.43M | 41.66M | 35.32M | 29.14M | 25.78M | 24.09M | 4.96M | 15.83M | 15.85M |
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical Business
Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates
Add These 4 Top-Ranked Liquid Stocks For Healthy Gains
5 Small Hidden Gems Flying High Despite Market's Bloodbath
5 Stocks to Bet on in an Innovation-Driven Drug Industry
Are Medical Stocks Lagging Aerie Pharmaceuticals (AERI) This Year?
AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI
Is Aerie Pharmaceuticals (AERI) Stock Outpacing Its Medical Peers This Year?
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AERI, ECOM, PFS, LBAI
Source: https://incomestatements.info
Category: Stock Reports